Paris: Sanofi and Glaxosmithkline said on Wednesday the dose of a single amplifier from the Covid-19 vaccine candidate they gave a strong immune response, the initial data from the clinical trial showed, encouragement for drug makers after masing the vaccine race.
French and English partners say they expect more results from the stage III final stage of the Covid-19 covid-19 recombinant vaccine candidate in the first quarter.
They plan to apply for booster data with regulatory authorities after the results of phase III.
“This booster is well tolerated, with a safety profile that is similar to the Covid-19 vaccine that is approved today.
This is the most comprehensive booster trial to date to explore the increase in different vaccine technology used for primary vaccination”, the company said in A statement.
“To provide the data needed for the Supervisory Authority to submit a booster vaccine, the trial will continue to increase the number of events needed for analysis, with the expected results in Q1.
2022.” There are no security problems identified.
This vaccine uses the same technology as one of the seasonal sanofi influenza vaccines plus adjuvant, a substance that acts as a booster against shots, made by GSK.
This news gave some optimism for the company after falling behind rivals in a race for Covid-19 shots and a major delay with the development of this shot.
Last year, trials for shots showed an inadequate immune response to parents.
Companies said the vaccine could be approved by the end of the year after initially targeting the first half of this year.
At the end of September, Sanofi dropped plans for MRNA-19-based Covid-19 vaccine because of the dominance achieved by Biotech-Pfizer and Moderna in using technology to fight a pandemic.
Booster Shot The Booster Shot has been tested for all age groups and for people who have received four most approved shots – Astrazeneca, Johnson & Johnson, Moderna and Pfizer / Bionth – as part of their main vaccine.
It was given between four and ten months after a complete main vaccination schedule.
Omicron variant is not circulating during the trial.
“The initial results of the VAT0002 clinical trial who investigated the safety and immunogenicity Booster showed antibodies that neutralized increased nine to 43-fold regardless of the main vaccine received (Astrazeneca, Johnson & Johnson, Moderna, Pfizer / Bontech) and for all age groups tested” said Sanofi.
The company said this was the most “comprehensive” Booster trial until now because European countries wrestle with a new wave of Covid-19 infection driven by Delta variants from viruses and preparing for more contagious omicron variants.
Sanofi also continued “his contribution to the health needs of the global public” by making up to half a billion doses of Vaccines BONONECH / PFIZER, MODICA, and JOHNSON & JOHNSON.